Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Seizures × Drug Therapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 33 Neoplasms 27 Colorectal Neoplasms 20 Breast Neoplasms 16 Ovarian Neoplasms 15 Pancreatic Neoplasms 13 Neoplasm Metastasis 12 Lung Neoplasms 11 Stomach Neoplasms 10 Leukemia, Myeloid, Acute 10 Melanoma 9 Lymphoma, Non-Hodgkin 8 Small Cell Lung Carcinoma 6 Recurrence 6 Liver Neoplasms 6 Leukemia 6 Head and Neck Neoplasms 6 Fallopian Tube Neoplasms 6 Prostatic Neoplasms 5 Glioblastoma 5 Cholangiocarcinoma 5 Adenocarcinoma 5 Urinary Bladder Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Sarcoma 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Lymphoma 4 Gastrointestinal Neoplasms 4 Uterine Cervical Neoplasms 3 Triple Negative Breast Neoplasms 3

Interventions

Cannabidiol 5 Everolimus 2 enzalutamide 1 Temozolomide 1 Standard of Care 1 Solutions 1 Lenalidomide 1 Drug Therapy 1 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04450160 2020-06-29

AEO

MetVital, Inc.

Phase 2 Unknown

Glioblastoma, Seizures

Data powered by HemOnc (CC BY 4.0) Colophon ⚡